Identification of metabolomics panels for potential lung cancer screening by analysis of exhaled breath condensate

Abstract

Exhaled breath condensate (EBC) is one of the less employed biofluids when searching for clinical markers, despite its non-invasive sampling and the potential relationship between its composition and respiratory disease phenotypes such as lung cancer. The advanced stage at which lung cancer is usually detected is the main reason for the high mortality rate of this carcinogenic disease. In this preliminary research, EBC was used as clinical sample to develop a screening tool for lung cancer discrimination from two control groups (with and without risk factor). Three panels of metabolites were configured using the PanelomiX tool to minimize false negatives (specificity) and false positives (sensitivity). The combination of five metabolites led to three panels providing a sensitivity above 77.9%, specificity above 67.5% and the area under the curve (AUC) above 77.5% for the three panels. An additional study was developed as a first approach to study the statistical significance of metabolites at different stages of lung cancer.

Detection of Lung Cancer and EGFR Mutation by Electronic Nose System

“…We also compared LC with benign nodules, with results similar to those from previous studies. 13,14,19,20,26,27 In our previous pilot study of patients from Colorado, we showed that benign pulmonary nodules could be well discriminated from LC by a unique breath print. 25 The nanoarray sensors could also discriminate between adenocarcinomas and SCCs and between early-stage and advanced disease.…”

“…In another interesting study performed by Peralbo-Molina et al, five different metabolites (monopalmitin, benzyl alcohol, monostearin, 2,4-diphenyl-4-methyl-2-E-pentene, and p-cresol) were used to form three panels. 27 Patients with LC were differentiated from healthy controls and patients with risk factors with a sensitivity higher than 77.9%, a specificity higher than 67.5% and an area under the curve higher than 77.5%.…”

Breath Metabolomics Provides an Accurate and Noninvasive Approach for Screening Cirrhosis, Primary, and Secondary Liver Tumors

“…Breath metabolomics has also shown promising results for detecting colon cancer, breast cancer, infectious disease, asthma, and others. (19)(20)(21)(22)(23)(24)(25) Here, we present a model developed from breathbased metabolites (volatile organic compounds [VOCs]) to classify patients as being healthy, having pulmonary hypertension (as a disease control), cirrhosis, HCC, or CRLM in a large and well-characterized cohort of patients with liver disease. We compare and contrast our model's prediction accuracy for detecting HCC to the current clinical standard, AFP, and examine the potential for breath metabolomics as a noninvasive screening tool for detecting liver diseases.…”

Adipsin, MIP-1b, and IL-8 as CSF Biomarker Panels for ALS Diagnosis

“…The proposed combination model has been demonstrated to be advantageous for predicting the outcome in patients with aneurysmal subarachnoid haemorrhage [ 22 ] and prognosis in severe traumatic brain injury [ 23 ]. Also, it has been applied to discriminate between patients with lung cancer versus smokers [ 24 , 25 ]. In a previous work, we reported the high values of MIP-1b and adipsin in patients with ALS [ 12 , 13 ].…”